Citations (177)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
Zifu Yao, Anqi Lin, Yonglin Yi, Weitao Shen, Jian Zhang & Peng Luo. (2022) THSD7B Mutation Induces Platinum Resistance in Small Cell Lung Cancer Patients. Drug Design, Development and Therapy 16, pages 1679-1695.
Read now
Read now
Anupam Batra & Eric Winquist. (2018) Emerging cell cycle inhibitors for treating metastatic castration-resistant prostate cancer. Expert Opinion on Emerging Drugs 23:4, pages 271-282.
Read now
Read now
Siqing Fu, Yudong Wang, Khandan Keyomarsi & Funda Meric-Bernstein. (2018) Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy. Expert Opinion on Investigational Drugs 27:9, pages 741-751.
Read now
Read now
Peter John Webster, Anna Tiffany Littlejohns, Hannah Jane Gaunt, K. Raj Prasad, David John Beech & Dermot Anthony Burke. (2017) AZD1775 induces toxicity through double-stranded DNA breaks independently of chemotherapeutic agents in p53-mutated colorectal cancer cells. Cell Cycle 16:22, pages 2176-2182.
Read now
Read now
Fabio Barra, Domenica Lorusso, Umberto Leone Roberti Maggiore, Antonino Ditto, Giorgio Bogani, Francesco Raspagliesi & Simone Ferrero. (2017) Investigational drugs for the treatment of cervical cancer. Expert Opinion on Investigational Drugs 26:4, pages 389-402.
Read now
Read now
Qing Chang, Megha Chandrashekhar, Troy Ketela, Yaroslav Fedyshyn, Jason Moffat & David Hedley. (2016) Cytokinetic effects of Wee1 disruption in pancreatic cancer. Cell Cycle 15:4, pages 593-604.
Read now
Read now
Roberta Visconti, Rosa Della Monica & Domenico Grieco. (2016) Sustaining the spindle assembly checkpoint to improve cancer therapy. Molecular & Cellular Oncology 3:1.
Read now
Read now
Wenxiu Qi, Wenbo Zhang, Holly Edwards, Roland Chu, Gerard J Madlambayan, Jeffrey W Taub, Zhihong Wang, Yue Wang, Chunhuai Li, Hai Lin & Yubin Ge. (2015) Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo. Cancer Biology & Therapy 16:12, pages 1784-1793.
Read now
Read now
Paul Dent. (2014) Not so WEE. Cancer Biology & Therapy 15:4, pages 351-352.
Read now
Read now
Paola Indovina, Eleonora Marcelli, Domenico Di Marzo, Nadia Casini, Iris Maria Forte, Francesca Giorgi, Luigi Alfano, Francesca Pentimalli & Antonio Giordano. (2014) Abrogating G2/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma. Cancer Biology & Therapy 15:4, pages 380-388.
Read now
Read now
Khanh Do, James H. Doroshow & Shivaani Kummar. (2013) Wee1 kinase as a target for cancer therapy. Cell Cycle 12:19, pages 3348-3353.
Read now
Read now
Binghai Chen, Lujing Duan, Guangming Yin, Jing Tan & Xianzhen Jiang. (2013) miR-381, a novel intrinsic WEE1 inhibitor, sensitizes renal cancer cells to 5-FU by up-regulation of Cdc2 activities in 786-O. Journal of Chemotherapy 25:4, pages 229-238.
Read now
Read now
Soley Bayraktar & Caio M Rocha Lima. (2012) Emerging cell-cycle inhibitors for pancreatic cancer therapy. Expert Opinion on Emerging Drugs 17:4, pages 571-582.
Read now
Read now
Aki Iwai, Dimitra Bourboulia, Mehdi Mollapour, Sandra Jensen-Taubman, Sunmin Lee, Alison C. Donnelly, Soichiro Yoshida, Naoto Miyajima, Shinji Tsutsumi, Armine K. Smith, David Sun, Xiaolin Wu, Brian S. Blagg, Jane B. Trepel, William G. Stetler-Stevenson & Len Neckers. (2012) Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cells. Cell Cycle 11:19, pages 3649-3655.
Read now
Read now
Martina Cozzi, Francesca Giorgi, Eleonora Marcelli, Francesca Pentimalli, Iris Maria Forte, Silvia Schenone, Vittorio D’Urso, Giulia De Falco, Maurizio Botta, Antonio Giordano & Paola Indovina. (2012) Antitumor activity of new pyrazolo[3,4-d]pyrimidine SRC kinase inhibitors in Burkitt lymphoma cell lines and its enhancement by WEE1 inhibition. Cell Cycle 11:5, pages 1029-1039.
Read now
Read now
Articles from other publishers (162)
Drumond-Bock Ana Luiza, Wang Luyao, Wang Lin, Cybula Magdalena, Rostworowska Maria, Kinter Michael & Bieniasz Magdalena. (2023) Increased expression of BRD4 isoforms long (BRD4-L) and short (BRD4-S) promotes chemotherapy resistance in high-grade serous ovarian carcinoma. Genes & Cancer 14, pages 56-76.
Crossref
Crossref
Man Liu, Na Li, Hongzhen Tang, Luohai Chen, Xuemei Liu, Yu Wang, Yuan Lin, Yanji Luo, Shaozhen Wei, Wenli Wen, Minhu Chen, Jiaqian Wang, Ning Zhang & Jie Chen. (2023) The Mutational, Prognostic, and Therapeutic Landscape of Neuroendocrine Neoplasms. The Oncologist 28:9, pages e723-e736.
Crossref
Crossref
Eduardo Gonzalez-Ochoa, Michael Milosevic, Bradley Corr, James L Abbruzzese, Eugenia Girda, Rachel W Miller, Jennifer Croke, Helen Mackay, Yeh Chen Lee, Valerie Bowering, Janelle Ramsahai, Lisa Wang, April D'Souza, Charles A Kunos, Amit M Oza & Stephanie Lheureux. (2023) A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers. International Journal of Gynecologic Cancer 33:8, pages 1208-1214.
Crossref
Crossref
Alaa Embaby, Joachim Kutzera, Jill J. Geenen, Dick Pluim, Ingrid Hofland, Joyce Sanders, Marta Lopez-Yurda, Jos H. Beijnen, Alwin D.R. Huitema, Petronella O. Witteveen, Neeltje Steeghs, Gijs van Haaften, Marcel A.T.M. van Vugt, Jeroen de Ridder & Frans L. Opdam. (2023) WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study. Gynecologic Oncology 174, pages 239-246.
Crossref
Crossref
Todd M. Bauer, Kathleen N. Moore, Janet S. Rader, Fiona Simpkins, Alain C. Mita, J. Thaddeus Beck, Lowell Hart, Quincy Chu, Amit Oza, Anna V. Tinker, Esteban Rodrigo Imedio, Sanjeev Kumar, Ganesh Mugundu, Suzanne Jenkins, Juliann Chmielecki, Suzanne Jones, David Spigel & Siqing Fu. (2023) A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors. Targeted Oncology 18:4, pages 517-530.
Crossref
Crossref
Gerald S Falchook, Jasgit Sachdev, Esteban Rodrigo Imedio, Sanjeev Kumar, Ganesh M Mugundu, Suzanne Jenkins, Juliann Chmielecki, Suzanne Jones, David R Spigel & Melissa Johnson. (2023) A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors. Investigational New Drugs 41:3, pages 493-502.
Crossref
Crossref
Monika Lukoseviciute, Aikaterini Theodosopoulou, Stefan Holzhauser, Tina Dalianis & Ourania Kostopoulou. (2023) Combination of PARP and WEE1 inhibitors in vitro: Potential for use in the treatment of SHH medulloblastoma. Oncology Reports 49:6.
Crossref
Crossref
Shigeto Nishikawa & Tomoo Iwakuma. (2023) Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials. Cancers 15:2, pages 429.
Crossref
Crossref
Yuting Xue, Xuejiao Jiang, Junrong Wang, Yuxuan Zong, Zhennan Yuan, Susheng Miao & Xionghui Mao. (2023) Effect of regulatory cell death on the occurrence and development of head and neck squamous cell carcinoma. Biomarker Research 11:1.
Crossref
Crossref
Kaushiki Roy, Debapriya Banik, Gordon K. Chan, Ondrej Krejcar & Debotosh Bhattacharjee. (2023) 2pClPr: A Two-Phase Clump Profiler for Segmentation of Cancer Cells in Fluorescence Microscopic Images. IEEE Transactions on Instrumentation and Measurement 72, pages 1-14.
Crossref
Crossref
Alexandre André B. A. da Costa, Dipanjan Chowdhury, Geoffrey I. Shapiro, Alan D. D’Andrea & Panagiotis A. Konstantinopoulos. (2022) Targeting replication stress in cancer therapy. Nature Reviews Drug Discovery 22:1, pages 38-58.
Crossref
Crossref
Siyao Deng, Tijana Vlatkovic, Moying Li, Tianzuo Zhan, Marlon R. Veldwijk & Carsten Herskind. (2022) Targeting the DNA Damage Response and DNA Repair Pathways to Enhance Radiosensitivity in Colorectal Cancer. Cancers 14:19, pages 4874.
Crossref
Crossref
Shihan N. Khan, Paul L. Swiecicki & Deborah B. Doroshow. (2022) Mitotic Checkpoints and the Role of WEE1 Inhibition in Head and Neck Squamous Cell Carcinoma. The Cancer Journal 28:5, pages 381-386.
Crossref
Crossref
Jin Gu Cho, Sung-wook Kim, Aram Lee, Ha-neul Jeong, Eunsik Yun, Jihea Choi, Su Jin Jeong, Woochul Chang, Sumin Oh, Kyung Hyun Yoo, Jung Bok Lee, Sukjoon Yoon, Myeong-Sok Lee, Jong Hoon Park, Min Hyung Jung, So-Woon Kim, Ki Hyung Kim, Dong Soo Suh, Kyung Un Choi, Jungmin Choi, Jongmin Kim & Byung Su Kwon. (2022) MicroRNA-dependent inhibition of WEE1 controls cancer stem-like characteristics and malignant behavior in ovarian cancer. Molecular Therapy - Nucleic Acids 29, pages 803-822.
Crossref
Crossref
Myungyeon Lee, Na Yeon Ham, Chi Yeon Hwang, Jiwon Jang, Boram Lee, Joo-Won Jeong, Insug Kang & Eui-Ju Yeo. (2022) Compound C Inhibits Renca Renal Epithelial Carcinoma Growth in Syngeneic Mouse Models by Blocking Cell Cycle Progression, Adhesion and Invasion. International Journal of Molecular Sciences 23:17, pages 9675.
Crossref
Crossref
Bo Lv, Ruijie Xu, Xinrui Xing, Chuyao Liao, Zunjian Zhang, Pei Zhang & Fengguo Xu. (2022) Discovery of Synergistic Drug Combinations for Colorectal Cancer Driven by Tumor Barcode Derived from Metabolomics “Big Data”. Metabolites 12:6, pages 494.
Crossref
Crossref
Rachel Abbotts, Anna J. Dellomo & Feyruz V. Rassool. (2022) Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use. Cancers 14:11, pages 2640.
Crossref
Crossref
Luisa Maresca, Barbara Stecca & Laura Carrassa. (2022) Novel Therapeutic Approaches with DNA Damage Response Inhibitors for Melanoma Treatment. Cells 11:9, pages 1466.
Crossref
Crossref
Zejia Yang, Jipei Liao, Rena G. Lapidus, Xiaoxuan Fan, Ranee Mehra, Kevin J. Cullen & Hancai Dan. (2022) Targeting Wee1 kinase to suppress proliferation and survival of cisplatin-resistant head and neck squamous cell carcinoma. Cancer Chemotherapy and Pharmacology 89:4, pages 469-478.
Crossref
Crossref
Keitaro Miyake, Naoharu Takano, Hiromi Kazama, Hiroyuki Kikuchi, Masaki Hiramoto, Kiyoaki Tsukahara & Keisuke Miyazawa. (2022) Ricolinostat enhances adavosertib‑induced mitotic catastrophe in TP53‑mutated head and neck squamous cell carcinoma cells. International Journal of Oncology 60:5.
Crossref
Crossref
Narayan Pokhrel, Olga Genin, Dalit Sela-Donenfeld & Yuval Cinnamon. (2022) HREM, RNAseq and Cell Cycle Analyses Reveal the Role of the G2/M-Regulatory Protein, WEE1, on the Survivability of Chicken Embryos during Diapause. Biomedicines 10:4, pages 779.
Crossref
Crossref
Amirali B. Bukhari, Gordon K. Chan & Armin M. Gamper. (2022) Targeting the DNA Damage Response for Cancer Therapy by Inhibiting the Kinase Wee1. Frontiers in Oncology 12.
Crossref
Crossref
Stina George Fernandes, Prachi Shah & Ekta Khattar. (2022) Recent Advances in Therapeutic Application of DNA Damage Response Inhibitors
against Cancer. Anti-Cancer Agents in Medicinal Chemistry 22:3, pages 469-484.
Crossref
Crossref
Kathleen N. Moore, Setsuko K. Chambers, Erika P. Hamilton, Lee-may Chen, Amit M. Oza, Sharad A. Ghamande, Gottfried E. Konecny, Steven C. Plaxe, Daniel L. Spitz, Jill J.J. Geenen, Tiffany A. Troso-Sandoval, Janiel M. Cragun, Esteban Rodrigo Imedio, Sanjeev Kumar, Ganesh M. Mugundu, Zhongwu Lai, Juliann Chmielecki, Suzanne F. Jones, David R. Spigel & Karen A. Cadoo. (2022) Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study. Clinical Cancer Research 28:1, pages 36-44.
Crossref
Crossref
Sabine Mueller, Tabitha Cooney, Xiaodong Yang, Sharmistha Pal, Ralph Ermoian, Amar Gajjar, Xiaowei Liu, Komal Prem, Charles G Minard, Joel M Reid, Marvin Nelson, Daphne Haas-Kogan, Elizabeth Fox & Brenda J Weigel. (2022) Wee1 kinase inhibitor adavosertib with radiation in newly diagnosed diffuse intrinsic pontine glioma: A Children’s Oncology Group phase I consortium study. Neuro-Oncology Advances 4:1.
Crossref
Crossref
Sajjad Vakili-Samiani, Abduladheem Turki Jalil, Walid Kamal Abdelbasset, Alexei Valerievich Yumashev, Vahid Karpisheh, Pooya Jalali, Sara Adibfar, Majid Ahmadi, Abbas Ali Hosseinpour Feizi & Farhad Jadidi-Niaragh. (2021) Targeting Wee1 kinase as a therapeutic approach in Hematological Malignancies. DNA Repair 107, pages 103203.
Crossref
Crossref
Francesca Esposito, Raffaella Giuffrida, Gabriele Raciti, Caterina Puglisi & Stefano Forte. (2021) Wee1 Kinase: A Potential Target to Overcome Tumor Resistance to Therapy. International Journal of Molecular Sciences 22:19, pages 10689.
Crossref
Crossref
Natalie Y.L. Ngoi, Melissa M. Pham, David S.P. Tan & Timothy A. Yap. (2021) Targeting the replication stress response through synthetic lethal strategies in cancer medicine. Trends in Cancer 7:10, pages 930-957.
Crossref
Crossref
Naoko Takebe, Abdul Rafeh Naqash, Geraldine O'Sullivan Coyne, Shivaani Kummar, Khanh Do, Ashley Bruns, Lamin Juwara, Jennifer Zlott, Larry Rubinstein, Richard Piekarz, Elad Sharon, Howard Streicher, Arjun Mittra, Sarah B. Miller, Jiuping Ji, Deborah Wilsker, Robert J. Kinders, Ralph E. Parchment, Li Chen, Ting-Chia Chang, Biswajit Das, Ganesh Mugundu, James H. Doroshow & Alice P. Chen. (2021) Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors. Clinical Cancer Research 27:14, pages 3834-3844.
Crossref
Crossref
Yassi Fallah, Diane M. Demas, Lu Jin, Wei He & Ayesha N. Shajahan-Haq. (2021) Targeting WEE1 Inhibits Growth of Breast Cancer Cells That Are Resistant to Endocrine Therapy and CDK4/6 Inhibitors. Frontiers in Oncology 11.
Crossref
Crossref
Salma K Jabbour, Terence M Williams, Mutlay Sayan, Eric D Miller, Jaffer A Ajani, Andrew C Chang, Norman Coleman, Wael El-Rifai, Michael Haddock, David Ilson, Daniel Jamorabo, Charles Kunos, Steven Lin, Geoffrey Liu, Pataje G Prasanna, Anil K Rustgi, Rosemary Wong, Bhadrasain Vikram & Mansoor M Ahmed. (2021) Potential Molecular Targets in the Setting of Chemoradiation for Esophageal Malignancies. JNCI: Journal of the National Cancer Institute 113:6, pages 665-679.
Crossref
Crossref
Sarah J. Hartman, Stacey M. Bagby, Betelehem W. Yacob, Dennis M. Simmons, Morgan MacBeth, Christopher H. Lieu, S. Lindsey Davis, Alexis D. Leal, John J. Tentler, Jennifer R. Diamond, S. Gail Eckhardt, Wells A. Messersmith & Todd M. Pitts. (2021) WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma. Frontiers in Oncology 11.
Crossref
Crossref
Robert F. Gruener, Alexander Ling, Ya-Fang Chang, Gladys Morrison, Paul Geeleher, Geoffrey L. Greene & R. Stephanie Huang. (2021) Facilitating Drug Discovery in Breast Cancer by Virtually Screening Patients Using In Vitro Drug Response Modeling. Cancers 13:4, pages 885.
Crossref
Crossref
Tanya E. Keenan, Tianyu Li, Tuulia Vallius, Jennifer L. Guerriero, Nabihah Tayob, Bose Kochupurakkal, Janae Davis, Ricardo Pastorello, Rie K. Tahara, Leilani Anderson, Jake Conway, Meng X. He, Erin Shannon, Robert E. Godin, Peter K. Sorger, Alan D'Andrea, Beth Overmoyer, Eric P. Winer, Elizabeth A. Mittendorf, Eliezer M. Van Allen, Geoffrey I. Shapiro & Sara M. Tolaney. (2021) Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer. Clinical Cancer Research 27:4, pages 983-991.
Crossref
Crossref
Lukas Gorecki, Martin Andrs & Jan Korabecny. (2021) Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in Cancer. Cancers 13:4, pages 795.
Crossref
Crossref
Michèle J. Hoffmann, Sarah Meneceur, Katrin Hommel, Wolfgang A. Schulz & Günter Niegisch. (2021) Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells. Genes 12:2, pages 260.
Crossref
Crossref
Christina R. Washington, Debra L. Richardson, Amma F. Agyemang, Kunle O. Odunsi & Kathleen N. Moore. 2021. Overcoming Ovarian Cancer Chemoresistance. Overcoming Ovarian Cancer Chemoresistance
129
149
.
Jenna L. Carter, Katie Hege, Jay Yang, Hasini A. Kalpage, Yongwei Su, Holly Edwards, Maik Hüttemann, Jeffrey W. Taub & Yubin Ge. (2020) Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy. Signal Transduction and Targeted Therapy 5:1.
Crossref
Crossref
Andrea Ghelli Luserna di Rorà, Claudio Cerchione, Giovanni Martinelli & Giorgia Simonetti. (2020) A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target. Journal of Hematology & Oncology 13:1.
Crossref
Crossref
Ahmed Diab, Hakan Gem, Jherek Swanger, Hee Yeon Kim, Kaleb SmithGrace ZouSharat RajuMichael KaoMatthew FitzgibbonKeith R. Loeb, Cristina P. Rodriguez, Eduardo MéndezDenise A. Galloway, Julia M. SidorovaBruce E. Clurman. (2020) FOXM1 drives HPV+ HNSCC sensitivity to WEE1 inhibition. Proceedings of the National Academy of Sciences 117:45, pages 28287-28296.
Crossref
Crossref
Yannick P. Kok, Sergi Guerrero Llobet, Pepijn M. Schoonen, Marieke Everts, Arkajyoti Bhattacharya, Rudolf S. N. Fehrmann, Nathalie van den Tempel & Marcel A. T. M. van Vugt. (2020) Overexpression of Cyclin E1 or Cdc25A leads to replication stress, mitotic aberrancies, and increased sensitivity to replication checkpoint inhibitors. Oncogenesis 9:10.
Crossref
Crossref
Xingkai Du, Jian Li, Xiaojiao Luo, Rong Li, Feng Li, Yiwen Zhang, Jianyou Shi & Jun He. (2020) Structure-activity relationships of Wee1 inhibitors: A review. European Journal of Medicinal Chemistry 203, pages 112524.
Crossref
Crossref
Amit M. Oza, Maria Estevez-Diz, Eva-Maria Grischke, Marcia Hall, Frederik Marmé, Diane Provencher, Denise Uyar, Johanne I. Weberpals, Robert M. Wenham, Naomi Laing, Michael Tracy, Tomoko Freshwater, Mark A. Lee, Ji Liu, Jingjun Qiu, Shelonitda Rose, Eric H. Rubin & Kathleen Moore. (2020)
A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive
TP53
-mutant Ovarian Cancer
. Clinical Cancer Research 26:18, pages 4767-4776.
Crossref
Crossref
Bin Wang, Lin Sun, Zhiyong Yuan & Zhen Tao. (2020) Wee1 kinase inhibitor AZD1775 potentiates CD8+ T cell-dependent antitumour activity via dendritic cell activation following a single high dose of irradiation. Medical Oncology 37:8.
Crossref
Crossref
Daniel C. Moreira, Sujatha Venkataraman, Apurva Subramanian, John Desisto, Ilango Balakrishnan, Eric Prince, Angela Pierce, Andrea Griesinger, Adam Green, Charles G. Eberhardt, Nicholas K. Foreman & Rajeev Vibhakar. (2020) Targeting MYC-driven replication stress in medulloblastoma with AZD1775 and gemcitabine. Journal of Neuro-Oncology 147:3, pages 531-545.
Crossref
Crossref
Todd M. Pitts, Dennis M. Simmons, Stacey M. Bagby, Sarah J. Hartman, Betelehem W. Yacob, Brian Gittleman, John J. Tentler, Diana Cittelly, D. Ryan Ormond, Wells A. Messersmith, S. Gail Eckhardt & Jennifer R. Diamond. (2020) Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer. Cancers 12:3, pages 719.
Crossref
Crossref
Tamara B. Garcia, Rizvan C. Uluisik, Annemie A. van Linden, Kenneth L. Jones, Sujatha Venkataraman, Rajeev Vibhakar & Christopher C. Porter. (2020) Increased HDAC Activity and c-MYC Expression Mediate Acquired Resistance to WEE1 Inhibition in Acute Leukemia. Frontiers in Oncology 10.
Crossref
Crossref
Alexander Y. Deneka, Margret B. Einarson, John Bennett, Anna S. Nikonova, Mohamed Elmekawy, Yan Zhou, Jong Woo Lee, Barbara A. Burtness & Erica A. Golemis. (2020) Synthetic Lethal Targeting of Mitotic Checkpoints in HPV-Negative Head and Neck Cancer. Cancers 12:2, pages 306.
Crossref
Crossref
Mathilde R. W. de Jong, Myra Langendonk, Bart Reitsma, Pien Herbers, Monique Lodewijk, Marcel Nijland, Anke van den Berg, Emanuele Ammatuna, Lydia Visser & Tom van Meerten. (2020) WEE1 inhibition synergizes with CHOP chemotherapy and radiation therapy through induction of premature mitotic entry and DNA damage in diffuse large B-cell lymphoma. Therapeutic Advances in Hematology 11, pages 204062071989837.
Crossref
Crossref
Hannah L. Smith, Harriet Southgate, Deborah A. Tweddle & Nicola J. Curtin. (2020) DNA damage checkpoint kinases in cancer. Expert Reviews in Molecular Medicine 22.
Crossref
Crossref
Camilla R. Elbæk, Valdemaras Petrosius & Claus S. Sørensen. (2020) WEE1 kinase limits CDK activities to safeguard DNA replication and mitotic entry. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 819-820, pages 111694.
Crossref
Crossref
Abdullah A. Osman, Antje Lindemann, Li Wang, Steven J. Frank & Jeffrey N. Myers. 2020. Improving the Therapeutic Ratio in Head and Neck Cancer. Improving the Therapeutic Ratio in Head and Neck Cancer
65
88
.
Courtney Schott, Avanthi Tayi Shah & E. Alejandro Sweet-Cordero. 2020. Current Advances in the Science of Osteosarcoma. Current Advances in the Science of Osteosarcoma
1
19
.
Cody W. Lewis, Amirali B. Bukhari, Edric J. Xiao, Won-Shik Choi, Joanne D. Smith, Ellen Homola, John R. Mackey, Shelagh D. Campbell, Armin M. Gamper & Gordon K. Chan. (2019) Upregulation of Myt1 Promotes Acquired Resistance of Cancer Cells to Wee1 Inhibition. Cancer Research 79:23, pages 5971-5985.
Crossref
Crossref
Dongdong Liu, Jingyi Lai, Rui Wang, Ling Ye & Yang Tian. (2019)
Reverse Microemulsion Synthesis of Fe
3
O
4
–Ag
2
S Heteronanocrystals for Dual-Modal Imaging-Guided Photothermal Tumor Ablation
. ACS Biomaterials Science & Engineering 5:11, pages 6196-6206.
Crossref
Crossref
Rebecca S.S. Barbosa, Paola M. Dantonio, Taís Guimarães, Mariana B. de Oliveira, Veruska L. Fook Alves, Alex Freire Sandes, Rodrigo Carlini Fernando & Gisele W.B. Colleoni. (2019) Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines. Biochemical and Biophysical Research Communications 519:3, pages 597-604.
Crossref
Crossref
Jeeyun Lee, Seung Tae Kim, Kyung Kim, Hyuk Lee, Iwanka Kozarewa, Peter G.S. Mortimer, Justin I. Odegaard, Elizabeth A. Harrington, Juyoung Lee, Taehyang Lee, Sung Yong Oh, Jung-Hun Kang, Jung Hoon Kim, Youjin Kim, Jun Ho Ji, Young Saing Kim, Kyoung Eun Lee, Jinchul Kim, Tae Sung Sohn, Ji Yeong An, Min-Gew Choi, Jun Ho Lee, Jae Moon Bae, Sung Kim, Jae J. Kim, Yang Won Min, Byung-Hoon Min, Nayoung K.D. Kim, Sally Luke, Young Hwa Kim, Jung Yong Hong, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, AmirAli Talasaz, Simon J. Hollingsworth, Kyoung-Mee Kim & Won Ki Kang. (2019) Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial. Cancer Discovery 9:10, pages 1388-1405.
Crossref
Crossref
Moyan Hu, Boris Jovanović & Dušan Palić. (2019) In silico prediction of MicroRNA role in regulation of Zebrafish (Danio rerio) responses to nanoparticle exposure. Toxicology in Vitro 60, pages 187-202.
Crossref
Crossref
Shuning Bi, Qiuren Wei, Zhijun Zhao, Liang Chen, Chaojie Wang & Songqiang Xie. (2019) Wee1 Inhibitor AZD1775 Effectively Inhibits the Malignant Phenotypes of Esophageal Squamous Cell Carcinoma In Vitro and In Vivo. Frontiers in Pharmacology 10.
Crossref
Crossref
Shuang-Shuang Guo, Ying Wang & Qing-Xia Fan. (2019) Raddeanin A promotes apoptosis and ameliorates 5-fluorouracil resistance in cholangiocarcinoma cells. World Journal of Gastroenterology 25:26, pages 3380-3391.
Crossref
Crossref
Jong Woo Lee, Janaki Parameswaran, Teresa Sandoval-Schaefer, Kyung Jin Eoh, Dong-hua Yang, Fang Zhu, Ranee Mehra, Roshan Sharma, Stephen G. Gaffney, Elizabeth B. Perry, Jeffrey P. Townsend, Ilya G. Serebriiskii, Erica A. Golemis, Natalia Issaeva, Wendell G. Yarbrough, Ja Seok Koo & Barbara Burtness. (2019) Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research 25:11, pages 3430-3442.
Crossref
Crossref
Ahmed Diab, Michael Kao, Keffy Kehrli, Hee Yeon Kim, Julia Sidorova & Eduardo Mendez. (2019) Multiple Defects Sensitize p53-Deficient Head and Neck Cancer Cells to the WEE1 Kinase Inhibition. Molecular Cancer Research 17:5, pages 1115-1128.
Crossref
Crossref
Hanne DueAnna Amanda Schönherz, Laura RyøMaria Nascimento PrimoDitte Starberg JespersenEmil Aagaard ThomsenAnne Stidholt RougMin XiaoXiaohong TanYuyang PangKen H. YoungMartin BøgstedJacob Giehm MikkelsenKaren Dybkær. (2019) MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma. Blood Advances 3:7, pages 1185-1196.
Crossref
Crossref
Andrea Ghelli Luserna Di Rorà, Neil Beeharry, Enrica Imbrogno, Anna Ferrari, Valentina Robustelli, Simona Righi, Elena Sabattini, Maria Vittoria Verga Falzacappa, Chiara Ronchini, Nicoletta Testoni, Carmen Baldazzi, Cristina Papayannidis, Maria Chiara Abbenante, Giovanni Marconi, Stefania Paolini, Sarah Parisi, Chiara Sartor, Maria Chiara Fontana, Serena De Matteis, Ilaria Iacobucci, Pier Giuseppe Pelicci, Michele Cavo, Timothy J. Yen & Giovanni Martinelli. (2018) Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia. Journal of Hematology & Oncology 11:1.
Crossref
Crossref
Dennis Lindenblatt, Nastassja Terraneo, Giovanni Pellegrini, Susan Cohrs, Philipp René Spycher, David Vukovic, Martin Béhé, Roger Schibli & Jürgen Grünberg. (2018) Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma. BMC Cancer 18:1.
Crossref
Crossref
Kaitlin R. Carroll, Eileen E. Elfers, Joseph J. Stevens, Jonathan P. McNally, David A. Hildeman, Michael B. Jordan & Jonathan D. Katz. (2018) Extending Remission and Reversing New-Onset Type 1 Diabetes by Targeted Ablation of Autoreactive T Cells. Diabetes 67:11, pages 2319-2328.
Crossref
Crossref
Meng-Ling Yuan, Pei Li, Zi-Hao Xing, Jin-Ming Di, Hui Liu, An-Kui Yang, Xi-Jun Lin, Qi-Wei Jiang, Yang Yang, Jia-Rong Huang, Kun Wang, Meng-Ning Wei, Yao Li, Jin Ye & Zhi Shi. (2018) Inhibition of WEE1 Suppresses the Tumor Growth in Laryngeal Squamous Cell Carcinoma. Frontiers in Pharmacology 9.
Crossref
Crossref
Estefania Carrasco-Garcia, Isabel Martinez-Lacaci, Leticia Mayor-López, Elena Tristante, Mar Carballo-Santana, Pilar García-Morales, Maria Ventero Martin, Maria Fuentes-Baile, Álvaro Rodriguez-Lescure & Miguel Saceda. (2018) PDGFR and IGF-1R Inhibitors Induce a G2/M Arrest and Subsequent Cell Death in Human Glioblastoma Cell Lines. Cells 7:9, pages 131.
Crossref
Crossref
Mohammad Mirza-Aghazadeh-Attari, Saber Ghazizadeh Darband, Mojtaba Kaviani, Ainaz Mihanfar, Javad Aghazadeh Attari, Bahman Yousefi & Maryam Majidinia. (2018) DNA damage response and repair in colorectal cancer: Defects, regulation and therapeutic implications. DNA Repair 69, pages 34-52.
Crossref
Crossref
Nader Sanai, Jing Li, Julie Boerner, Karri Stark, Jianmei Wu, Seongho Kim, Alanna Derogatis, Shwetal Mehta, Harshil D. Dhruv, Lance K. Heilbrun, Michael E. Berens & Patricia M. LoRusso. (2018) Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients. Clinical Cancer Research 24:16, pages 3820-3828.
Crossref
Crossref
Eduardo Méndez, Cristina P. Rodriguez, Michael C. Kao, Sharat Raju, Ahmed Diab, R. Alex Harbison, Eric Q. Konnick, Ganesh M. Mugundu, Rafael Santana-Davila, Renato Martins, Neal D. Futran & Laura Q.M. Chow. (2018) A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research 24:12, pages 2740-2748.
Crossref
Crossref
Dongshao Chen, Xiaoting Lin, Jing Gao, Lin Shen, Zhongwu Li, Bin Dong, Cheng Zhang & Xiaotian Zhang. (2018) Wee1 Inhibitor AZD1775 Combined with Cisplatin Potentiates Anticancer Activity against Gastric Cancer by Increasing DNA Damage and Cell Apoptosis. BioMed Research International 2018, pages 1-10.
Crossref
Crossref
A. Lindemann, H. Takahashi, A.A. Patel, A.A. Osman & J.N. Myers. (2018)
Targeting the DNA Damage Response in OSCC with
TP
53 Mutations
. Journal of Dental Research 97:6, pages 635-644.
Crossref
Crossref
Yusuke Oku, Naoyuki Nishiya, Takaaki Tazawa, Takaya Kobayashi, Nanami Umezawa, Yasuyo Sugawara & Yoshimasa Uehara. (2018)
Augmentation of the therapeutic efficacy of
WEE
1 kinase inhibitor
AZD
1775 by inhibiting the
YAP
–E2F1–
DNA
damage response pathway axis
. FEBS Open Bio 8:6, pages 1001-1012.
Crossref
Crossref
Xiangbing Meng, Jianling Bi, Yujun Li, Shujie Yang, Yuping Zhang, Mary Li, Haitao Liu, Yiyang Li, Megan Mcdonald, Kristina Thiel, Kuo-Kuang Wen, Xinhao Wang, Meng Wu & Kimberly Leslie. (2018) AZD1775 Increases Sensitivity to Olaparib and Gemcitabine in Cancer Cells with p53 Mutations. Cancers 10:5, pages 149.
Crossref
Crossref
Shaofang Wu, Shuzhen Wang, Feng Gao, Luyuan Li, Siyuan Zheng, W K Alfred Yung & Dimpy Koul. (2018) Activation of WEE1 confers resistance to PI3K inhibition in glioblastoma. Neuro-Oncology 20:1, pages 78-91.
Crossref
Crossref
David A. Gillespie. 2018. Targeting the DNA Damage Response for Anti-Cancer Therapy. Targeting the DNA Damage Response for Anti-Cancer Therapy
209
240
.
Yunping Yin, Qian Shen, Ruikang Tao, Weilong Chang, Ruidong Li, Gengchen Xie, Weizhen Liu, Peng Zhang & Kaixiong Tao. (2017) Wee1 inhibition can suppress tumor proliferation and sensitize p53 mutant colonic cancer cells to the anticancer effect of irinotecan. Molecular Medicine Reports.
Crossref
Crossref
Nupam P. Mahajan, Pavani Malla, Shambhavi Bhagwat, Vasundhara Sharma, Amod Sarnaik, Jongphil Kim, Shari Pilon-Thomas, Jeffery Weber & Kiran Mahajan. (2017)
WEE1 epigenetically modulates 5-hmC levels by pY37-H2B dependent regulation of
IDH2
gene expression
. Oncotarget 8:63, pages 106352-106368.
Crossref
Crossref
A. Ghelli Luserna di Rora’, I. Iacobucci & G. Martinelli. (2017) The cell cycle checkpoint inhibitors in the treatment of leukemias. Journal of Hematology & Oncology 10:1.
Crossref
Crossref
Matthias Schmidt, Alexander Rohe, Charlott Platzer, Abdulkarim Najjar, Frank Erdmann & Wolfgang Sippl. (2017) Regulation of G2/M Transition by Inhibition of WEE1 and PKMYT1 Kinases. Molecules 22:12, pages 2045.
Crossref
Crossref
Josephine Hai, Shengwu Liu, Lauren Bufe, Khanh Do, Ting Chen, Xiaoen Wang, Christine Ng, Shuai Li, Ming-Sound Tsao, Geoffrey I. Shapiro & Kwok-Kin Wong. (2017)
Synergy of WEE1 and mTOR Inhibition in Mutant
KRAS
-Driven Lung Cancers
. Clinical Cancer Research 23:22, pages 6993-7005.
Crossref
Crossref
Xiang Tan, Lei Dai, Yongyong Wang, Guanbiao Liang, Nuo Yang & Mingwu Chen. (2017) Responses to crizotinib and disease monitoring with circulating tumor cells in lung adenocarcinoma patient with MET exon 14 skipping mutation. Medicine 96:47, pages e8744.
Crossref
Crossref
Laura Carrassa & Giovanna Damia. (2017) DNA damage response inhibitors: Mechanisms and potential applications in cancer therapy. Cancer Treatment Reviews 60, pages 139-151.
Crossref
Crossref
Triparna Sen, Pan Tong, Lixia Diao, Lerong Li, Youhong Fan, Jennifer Hoff, John V. Heymach, Jing Wang & Lauren Averett Byers. (2017) Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer. Clinical Cancer Research 23:20, pages 6239-6253.
Crossref
Crossref
Tamara B. Garcia, Jonathan C. Snedeker, Dmitry Baturin, Lori Gardner, Susan P. Fosmire, Chengjing Zhou, Craig T. Jordan, Sujatha Venkataraman, Rajeev Vibhakar & Christopher C. Porter. (2017) A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia. Molecular Cancer Therapeutics 16:10, pages 2058-2068.
Crossref
Crossref
Carter Van Waes & Omar Musbahi. (2017) Genomics and advances towards precision medicine for head and neck squamous cell carcinoma. Laryngoscope Investigative Otolaryngology 2:5, pages 310-319.
Crossref
Crossref
Jin-Yi Zhu, Rebecca A. Cuellar, Norbert Berndt, Hee Eun Lee, Sanne H. Olesen, Mathew P. Martin, Jeffrey T. Jensen, Gunda I. Georg & Ernst Schönbrunn. (2017) Structural Basis of Wee Kinases Functionality and Inactivation by Diverse Small Molecule Inhibitors. Journal of Medicinal Chemistry 60:18, pages 7863-7875.
Crossref
Crossref
Minghui Zhang, Donye Dominguez, Siqi Chen, Jie Fan, Lei Qin, Alan Long, Xia Li, Yi Zhang, Huirong Shi & Bin Zhang. (2017) WEE1 inhibition by MK1775 as a single-agent therapy inhibits ovarian cancer viability. Oncology Letters 14:3, pages 3580-3586.
Crossref
Crossref
Jill J.J. Geenen & Jan H.M. Schellens. (2017) Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer. Clinical Cancer Research 23:16, pages 4540-4544.
Crossref
Crossref
Gabriela Wright, Volha Golubeva, Lily L. Remsing Rix, Norbert Berndt, Yunting Luo, Grace A. Ward, Jhanelle E. Gray, Ernst Schonbrunn, Harshani R. Lawrence, Alvaro N.A. Monteiro & Uwe Rix. (2017) Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity. ACS Chemical Biology 12:7, pages 1883-1892.
Crossref
Crossref
Jonathan P. McNallyScott H. Millen, Vandana ChaturvediNora LakesCatherine E. TerrellEileen E. ElfersKaitlin R. CarrollSimon P. HoganPaul R. AndreassenJulie KanterCarl E. AllenMichael M. HenryJay N. GreenbergStephan LadischMichelle L. HermistonMichael JoyceDavid A. HildemanJonathan D. KatzMichael B. Jordan. (2017) Manipulating DNA damage-response signaling for the treatment of immune-mediated diseases. Proceedings of the National Academy of Sciences 114:24.
Crossref
Crossref
Xiao-Chuan Ge, Fan Wu, Wei-Tao Li, Xuan-Jin Zhu, Jian-Wei Liu & Bai-Lin Wang. (2017) Upregulation of WEE1 is a potential prognostic biomarker for patients with colorectal cancer. Oncology Letters 13:6, pages 4341-4348.
Crossref
Crossref
Joshua K. Sabari, Benjamin H. Lok, James H. Laird, John T. Poirier & Charles M. Rudin. (2017) Unravelling the biology of SCLC: implications for therapy. Nature Reviews Clinical Oncology 14:9, pages 549-561.
Crossref
Crossref
Cyril Ronco, Anthony R. Martin, Luc Demange & Rachid Benhida. (2017) ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells. MedChemComm 8:2, pages 295-319.
Crossref
Crossref
Sissel Hauge, Christian Naucke, Grete Hasvold, Mrinal Joel, Gro Elise Rødland, Petras Juzenas, Trond Stokke & Randi G. Syljuåsen. (2016) Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading. Oncotarget 8:7, pages 10966-10979.
Crossref
Crossref
Tobias Otto & Piotr Sicinski. (2017) Cell cycle proteins as promising targets in cancer therapy. Nature Reviews Cancer 17:2, pages 93-115.
Crossref
Crossref
Daniela Kramer, Nadine Stark, Ramona Schulz-Heddergott, Norman Erytch, Shelley Edmunds, Laura Roßmann, Holger Bastians, Nicole Concin, Ute M Moll & Matthias Dobbelstein. (2016) Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells. Cell Death & Differentiation 24:2, pages 300-316.
Crossref
Crossref
Daniel R. Wahl & Theodore S. Lawrence. (2017) Integrating chemoradiation and molecularly targeted therapy. Advanced Drug Delivery Reviews 109, pages 74-83.
Crossref
Crossref
Suzanne LeijenRobin M.J.M. van GeelAnna C. PavlickRaoul TibesLee RosenAlbiruni R. Abdul RazakRaymond LamTim DemuthShelonitda RoseMark A. LeeTomoko FreshwaterStuart ShumwayLi Wen LiangAmit M. OzaJan H.M. SchellensGeoffrey I. Shapiro. (2016) Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors. Journal of Clinical Oncology 34:36, pages 4371-4380.
Crossref
Crossref
Suzanne LeijenRobin M.J.M. van GeelGabe S. SonkeDaphne de JongEfraim H. RosenbergSerena MarchettiDick PluimErik van WerkhovenShelonitda RoseMark A. LeeTomoko FreshwaterJos H. BeijnenJan H.M. Schellens. (2016)
Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With
TP53
-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months
. Journal of Clinical Oncology 34:36, pages 4354-4361.
Crossref
Crossref
Roberta Visconti, Rosa Della Monica & Domenico Grieco. (2016) Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword. Journal of Experimental & Clinical Cancer Research 35:1.
Crossref
Crossref
Christopher J. Matheson, Donald S. Backos & Philip Reigan. (2016) Targeting WEE1 Kinase in Cancer. Trends in Pharmacological Sciences 37:10, pages 872-881.
Crossref
Crossref
Zachery R. Reichert, Daniel R. Wahl & Meredith A. Morgan. (2016) Translation of Targeted Radiation Sensitizers into Clinical Trials. Seminars in Radiation Oncology 26:4, pages 261-270.
Crossref
Crossref
Shruti Lal, Mahsa Zarei, Saswati N. Chand, Emanuela Dylgjeri, Nicole C. Mambelli-Lisboa, Michael J. Pishvaian, Charles J. Yeo, Jordan M. Winter & Jonathan R. Brody. (2016) WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner. Scientific Reports 6:1.
Crossref
Crossref
Hye-Young Kim, Yunhee Cho, HyeokGu Kang, Ye-Seal Yim, Seok-Jun Kim, Jaewhan Song & Kyung-Hee Chun. (2016) Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer. Oncotarget 7:31, pages 49902-49916.
Crossref
Crossref
Ankita Jhuraney, Nicholas T. Woods, Gabriela Wright, Lily Rix, Fumi Kinose, Jodi L. Kroeger, Elizabeth Remily-Wood, W. Douglas Cress, John M. Koomen, Stephen G. Brantley, Jhanelle E. Gray, Eric B. Haura, Uwe Rix & Alvaro N. Monteiro. (2016) PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer. Molecular Cancer Therapeutics 15:7, pages 1669-1681.
Crossref
Crossref
Rebecca S. Lescarbeau, Liang Lei, Katrina K. Bakken, Peter A. Sims, Jann N. Sarkaria, Peter Canoll & Forest M. White. (2016) Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma. Molecular Cancer Therapeutics 15:6, pages 1332-1343.
Crossref
Crossref
Yu-Hung Huang, Weidan Peng, Narumi Furuuchi, James B. DuHadaway, Masaya Jimbo, Andrea Pirritano, Charles J. Dunton, Gary S. Daum, Benjamin E. Leiby, Jonathan R. Brody & Janet A. Sawicki. (2016) Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy. Oncotarget 7:16, pages 21812-21824.
Crossref
Crossref
Christopher J. Matheson, Sujatha Venkataraman, Vladimir Amani, Peter S. Harris, Donald S. Backos, Andrew M. Donson, Michael F. Wempe, Nicholas K. Foreman, Rajeev Vibhakar & Philip Reigan. (2016) A WEE1 Inhibitor Analog of AZD1775 Maintains Synergy with Cisplatin and Demonstrates Reduced Single-Agent Cytotoxicity in Medulloblastoma Cells. ACS Chemical Biology 11:4, pages 921-930.
Crossref
Crossref
Erik S. Knudsen, Eileen M. O’Reilly, Jonathan R. Brody & Agnieszka K. Witkiewicz. (2016) Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. Gastroenterology 150:1, pages 48-63.
Crossref
Crossref
Jeffrey S. Ross, Laurie M. Gay, Sahar Nozad, Kai Wang, Siraj M. Ali, Ann Boguniewicz, Depinder Khaira, Adrienne Johnson, Julia A. Elvin, Jo-Anne Vergilio, James Suh, Vincent A. Miller & Philip J. Stephens. (2016) Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study. Breast Cancer Research and Treatment 155:2, pages 405-413.
Crossref
Crossref
Kiran Mahajan & Nupam P. Mahajan. (2015) Cross talk of tyrosine kinases with the DNA damage signaling pathways. Nucleic Acids Research 43:22, pages 10588-10601.
Crossref
Crossref
Anne Margriet HeijinkVincent A. BlomenXavier BisteauFabian DegenerFelipe Yu MatsushitaPhilipp Kaldis, Floris Foijer & Marcel A. T. M. van Vugt. (2015)
A haploid genetic screen identifies the G
1
/S regulatory machinery as a determinant of Wee1 inhibitor sensitivity
. Proceedings of the National Academy of Sciences 112:49, pages 15160-15165.
Crossref
Crossref
Hongyu Ma, Akihisa Takahashi, Yukihiko Sejimo, Akiko Adachi, Nobuteru Kubo, Mayu Isono, Yukari Yoshida, Tatsuaki Kanai, Tatsuya Ohno & Takashi Nakano. (2015) Targeting of Carbon Ion-Induced G2 Checkpoint Activation in Lung Cancer Cells Using Wee-1 Inhibitor MK-1775. Radiation Research 184:6, pages 660.
Crossref
Crossref
Gry Irene Magnussen, Elisabeth Emilsen, Karianne Giller Fleten, Birgit Engesæter, Viola Nähse-Kumpf, Roar Fjær, Ana Slipicevic & Vivi Ann Flørenes. (2015) Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma. BMC Cancer 15:1.
Crossref
Crossref
Noriaki Tanaka, Ameeta A. Patel, Jiping Wang, Mitchell J. Frederick, Nene N. Kalu, Mei Zhao, Alison L. Fitzgerald, Tong-xin Xie, Natalie L. Silver, Carlos Caulin, Ge Zhou, Heath D. Skinner, Faye M. Johnson, Jeffrey N. Myers & Abdullah A. Osman. (2015) Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins. Clinical Cancer Research 21:21, pages 4831-4844.
Crossref
Crossref
Khanh DoDeborah WilskerJiuping JiJennifer ZlottTomoko FreshwaterRobert J. KindersJerry CollinsAlice P. ChenJames H. DoroshowShivaani Kummar. (2015) Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors. Journal of Clinical Oncology 33:30, pages 3409-3415.
Crossref
Crossref
Tasneem Kausar, Jason S. Schreiber, David Karnak, Leslie A. Parsels, Joshua D. Parsels, Mary A. Davis, Lili Zhao, Jonathan Maybaum, Theodore S. Lawrence & Meredith A. Morgan. (2015) Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair. Neoplasia 17:10, pages 757-766.
Crossref
Crossref
Jan Benada & Libor Macurek. (2015) Targeting the Checkpoint to Kill Cancer Cells. Biomolecules 5:3, pages 1912-1937.
Crossref
Crossref
E. Kaur, J. Rajendra, S. Jadhav, E. Shridhar, J. S. Goda, A. Moiyadi & S. Dutt. (2015) Radiation-induced homotypic cell fusions of innately resistant glioblastoma cells mediate their sustained survival and recurrence. Carcinogenesis 36:6, pages 685-695.
Crossref
Crossref
A Vassilopoulos, Y Tominaga, H-Seok Kim, T Lahusen, B Li, H Yu, D Gius & C-X Deng. (2014) WEE1 murine deficiency induces hyper-activation of APC/C and results in genomic instability and carcinogenesis. Oncogene 34:23, pages 3023-3035.
Crossref
Crossref
Jenny L. Pokorny, David Calligaris, Shiv K. Gupta, Dennis O. IyekegbeJrJr, Dustin Mueller, Katrina K. Bakken, Brett L. Carlson, Mark A. Schroeder, Debra L. Evans, Zhenkun Lou, Paul A. Decker, Jeanette E. Eckel-Passow, Vincenzo Pucci, Bennett Ma, Stuart D. Shumway, William F. Elmquist, Nathalie Y.R. Agar & Jann N. Sarkaria. (2015) The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma. Clinical Cancer Research 21:8, pages 1916-1924.
Crossref
Crossref
Marieke Aarts, Ilirjana Bajrami, Maria T. Herrera-Abreu, Richard Elliott, Rachel Brough, Alan Ashworth, Christopher J. Lord & Nicholas C. Turner. (2015) Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways. Molecular Cancer Therapeutics 14:4, pages 865-876.
Crossref
Crossref
L Zhou, Y Zhang, S Chen, M Kmieciak, Y Leng, H Lin, K A Rizzo, C I Dumur, A Ferreira-Gonzalez, Y Dai & S Grant. (2014) A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations. Leukemia 29:4, pages 807-818.
Crossref
Crossref
Abdullah A. Osman, Marcus M. Monroe, Marcus V. Ortega Alves, Ameeta A. Patel, Panagiotis Katsonis, Alison L. Fitzgerald, David M. Neskey, Mitchell J. Frederick, Sang Hyeok Woo, Carlos Caulin, Teng-Kuei Hsu, Thomas O. McDonald, Marek Kimmel, Raymond E. Meyn, Olivier Lichtarge & Jeffrey N. Myers. (2015)
Wee-1 Kinase Inhibition Overcomes Cisplatin Resistance Associated with High-Risk
TP53
Mutations in Head and Neck Cancer through Mitotic Arrest Followed by Senescence
. Molecular Cancer Therapeutics 14:2, pages 608-619.
Crossref
Crossref
E Weisberg, A Nonami, Z Chen, F Liu, J Zhang, M Sattler, E Nelson, K Cowens, A L Christie, C Mitsiades, K-K Wong, Q Liu, N Gray & J D Griffin. (2014) Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. Leukemia 29:1, pages 27-37.
Crossref
Crossref
Guan Wang, Xiaojia Niu, Wenbo Zhang, J. Timothy Caldwell, Holly Edwards, Wei Chen, Jeffrey W. Taub, Lijing Zhao & Yubin Ge. (2015) Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer. Cancer Letters 356:2, pages 656-668.
Crossref
Crossref
Santosh S. Hanmod, Guan Wang, Holly Edwards, Steven A. Buck, Yubin Ge, Jeffrey W. Taub & Zhihong Wang. (2015) Targeting histone deacetylases (HDACs) and Wee1 for treating high-risk neuroblastoma. Pediatric Blood & Cancer 62:1, pages 52-59.
Crossref
Crossref
Wenxiu Qi, Chengzhi Xie, Chunhuai Li, J Timothy Caldwell, Holly Edwards, Jeffrey W Taub, Yue Wang, Hai Lin & Yubin Ge. (2014) CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells. Journal of Hematology & Oncology 7:1.
Crossref
Crossref
J. Timothy Caldwell, Holly Edwards, Steven A. Buck, Yubin Ge & Jeffrey W. Taub. (2014) Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia. Pediatric Blood & Cancer 61:10, pages 1767-1773.
Crossref
Crossref
Russell Moser, Chang Xu, Michael Kao, James Annis, Luisa Angelica Lerma, Christopher M. Schaupp, Kay E. Gurley, In Sock Jang, Asel Biktasova, Wendell G. Yarbrough, Adam A. Margolin, Carla Grandori, Christopher J. Kemp & Eduardo Méndez. (2014) Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer. Clinical Cancer Research 20:16, pages 4274-4288.
Crossref
Crossref
M.T. Dillon, J.S. Good & K.J. Harrington. (2014) Selective Targeting of the G2/M Cell Cycle Checkpoint to Improve the Therapeutic Index of Radiotherapy. Clinical Oncology 26:5, pages 257-265.
Crossref
Crossref
Shruti Lal, Richard A. Burkhart, Neil Beeharry, Vikram Bhattacharjee, Eric R. Londin, Joseph A. Cozzitorto, Carmella Romeo, Masaya Jimbo, Zoë A. Norris, Charles J. Yeo, Janet A. Sawicki, Jordan M. Winter, Isidore Rigoutsos, Timothy J. Yen & Jonathan R. Brody. (2014) HuR Posttranscriptionally Regulates WEE1: Implications for the DNA Damage Response in Pancreatic Cancer Cells. Cancer Research 74:4, pages 1128-1140.
Crossref
Crossref
Ramez N. EskanderKrishnansu S. Tewari. (2014) Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer. Journal of Gynecologic Oncology 25:3, pages 249.
Crossref
Crossref
Annemie A. Van Linden, Dmitry Baturin, James B. Ford, Susan P. Fosmire, Lori Gardner, Christopher Korch, Philip Reigan & Christopher C. Porter. (2013)
Inhibition of Wee1 Sensitizes Cancer Cells to Antimetabolite Chemotherapeutics
In Vitro
and
In Vivo
, Independent of p53 Functionality
. Molecular Cancer Therapeutics 12:12, pages 2675-2684.
Crossref
Crossref
Lianne E.M. Vriend, Philip C. De Witt Hamer, Cornelis J.F. Van Noorden & Thomas Würdinger. (2013) WEE1 inhibition and genomic instability in cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1836:2, pages 227-235.
Crossref
Crossref
Amy D. Guertin, Jing Li, Yaping Liu, Melissa S. Hurd, Alwin G. Schuller, Brian Long, Heather A. Hirsch, Igor Feldman, Yair Benita, Carlo Toniatti, Leigh Zawel, Stephen E. Fawell, D. Gary Gilliland & Stuart D. Shumway. (2013) Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy. Molecular Cancer Therapeutics 12:8, pages 1442-1452.
Crossref
Crossref
Marieke Aarts, Spiros Linardopoulos & Nicholas C Turner. (2013) Tumour selective targeting of cell cycle kinases for cancer treatment. Current Opinion in Pharmacology 13:4, pages 529-535.
Crossref
Crossref
Kiran Mahajan & Nupam P. Mahajan. (2013) WEE1 tyrosine kinase, a novel epigenetic modifier. Trends in Genetics 29:7, pages 394-402.
Crossref
Crossref
A Bhattacharya, U Schmitz, O Wolkenhauer, M Schönherr, Y Raatz & M Kunz. (2012) Regulation of cell cycle checkpoint kinase WEE1 by miR-195 in malignant melanoma. Oncogene 32:26, pages 3175-3183.
Crossref
Crossref
M Krajewska, A M Heijink, Y J W M Bisselink, R I Seinstra, H H W Silljé, E G E de Vries & M A T M van Vugt. (2012) Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination. Oncogene 32:24, pages 3001-3008.
Crossref
Crossref
Jenny M. Kreahling, Parastou Foroutan, Damon Reed, Gary Martinez, Tiffany Razabdouski, Marilyn M. Bui, Meera Raghavan, Douglas Letson, Robert J. Gillies & Soner Altiok. (2013) Wee1 Inhibition by MK-1775 Leads to Tumor Inhibition and Enhances Efficacy of Gemcitabine in Human Sarcomas. PLoS ONE 8:3, pages e57523.
Crossref
Crossref
C. KARLISCH, K. HARATI, A.M. CHROMIK, D. BULUT, L. KLEIN-HITPASS, O. GOERTZ, T. HIRSCH, M. LEHNHARDT, W. UHL & A. DAIGELER. (2013) Effects of TRAIL and taurolidine on apoptosis and proliferation in human rhabdomyosarcoma, leiomyosarcoma and epithelioid cell sarcoma. International Journal of Oncology 42:3, pages 945-956.
Crossref
Crossref
Viola Caretti, Lotte Hiddingh, Tonny Lagerweij, Pepijn Schellen, Phil W. Koken, Esther Hulleman, Dannis G. van Vuurden, W. Peter Vandertop, Gertjan J.L. Kaspers, David P. Noske & Thomas Wurdinger. (2013) WEE1 Kinase Inhibition Enhances the Radiation Response of Diffuse Intrinsic Pontine Gliomas. Molecular Cancer Therapeutics 12:2, pages 141-150.
Crossref
Crossref
Matthew S. Evans, SubbaRao V. Madhunapantula, Gavin P. Robertson & Joseph J. Drabick. 2013. Impact of Genetic Targets on Cancer Therapy. Impact of Genetic Targets on Cancer Therapy
223
255
.
Amy D Guertin, Melissa M Martin, Brian Roberts, Melissa Hurd, Xianlu Qu, Nathan R Miselis, Yaping Liu, Jing Li, Igor Feldman, Yair Benita, Andrew Bloecher, Carlo Toniatti & Stuart D Shumway. (2012) Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition. Cancer Cell International 12:1.
Crossref
Crossref
Yang Xu, Wei Fang, Wei Zeng, Suzanne Leijen & Eric J. Woolf. (2012) Evaluation of dried blood spot (DBS) technology versus plasma analysis for the determination of MK-1775 by HILIC-MS/MS in support of clinical studies. Analytical and Bioanalytical Chemistry 404:10, pages 3037-3048.
Crossref
Crossref
Lynn M. Pouliot, Yu-Chi Chen, Jennifer Bai, Rajarshi Guha, Scott E. Martin, Michael M. Gottesman & Matthew D. Hall. (2012) Cisplatin Sensitivity Mediated by WEE1 and CHK1 Is Mediated by miR-155 and the miR-15 Family. Cancer Research 72:22, pages 5945-5955.
Crossref
Crossref
Marieke Aarts, Rachel Sharpe, Isaac Garcia-Murillas, Heidrun Gevensleben, Melissa S. Hurd, Stuart D. Shumway, Carlo Toniatti, Alan Ashworth & Nicholas C. Turner. (2012) Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1. Cancer Discovery 2:6, pages 524-539.
Crossref
Crossref
C C Porter, J Kim, S Fosmire, C M Gearheart, A van Linden, D Baturin, V Zaberezhnyy, P R Patel, D Gao, A C Tan & J DeGregori. (2012) Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia. Leukemia 26:6, pages 1266-1276.
Crossref
Crossref
R H Medema & L Macůrek. (2011) Checkpoint control and cancer. Oncogene 31:21, pages 2601-2613.
Crossref
Crossref
Sireesha V. Garimella, Andrea Rocca & Stanley Lipkowitz. (2012) WEE1 Inhibition Sensitizes Basal Breast Cancer Cells to TRAIL-Induced Apoptosis. Molecular Cancer Research 10:1, pages 75-85.
Crossref
Crossref
Jenny M. Kreahling, Jennifer Y. Gemmer, Damon Reed, Douglas Letson, Marilyn Bui & Soner Altiok. (2012) MK1775, a Selective Wee1 Inhibitor, Shows Single-Agent Antitumor Activity against Sarcoma Cells. Molecular Cancer Therapeutics 11:1, pages 174-182.
Crossref
Crossref
C. S. Sorensen & R. G. Syljuasen. (2011) Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication. Nucleic Acids Research 40:2, pages 477-486.
Crossref
Crossref
Sandra Morandell & Michael B. Yaffe. 2012. Mechanisms of DNA Repair. Mechanisms of DNA Repair
289
314
.
Susan Ashwell. 2012. DNA Repair in Cancer Therapy. DNA Repair in Cancer Therapy
211
234
.
Bhaswati Sarcar, Soumen Kahali, Antony H. Prabhu, Stuart D. Shumway, Yang Xu, Tim Demuth & Prakash Chinnaiyan. (2011) Targeting Radiation-Induced G2 Checkpoint Activation with the Wee-1 Inhibitor MK-1775 in Glioblastoma Cell Lines. Molecular Cancer Therapeutics 10:12, pages 2405-2414.
Crossref
Crossref
Kathleen A. Bridges, Hiroshi Hirai, Carolyn A. Buser, Colin Brooks, Huifeng Liu, Thomas A. Buchholz, Jessica M. Molkentine, Kathryn A. Mason & Raymond E. Meyn. (2011) MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells. Clinical Cancer Research 17:17, pages 5638-5648.
Crossref
Crossref
Philip C. De Witt Hamer, Shahryar E. Mir, David Noske, Cornelis J.F. Van Noorden & Tom Würdinger. (2011) WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe. Clinical Cancer Research 17:13, pages 4200-4207.
Crossref
Crossref
N.V. Rajeshkumar, Elizabeth De Oliveira, Niki Ottenhof, James Watters, David Brooks, Tim Demuth, Stuart D. Shumway, Shinji Mizuarai, Hiroshi Hirai, Anirban Maitra & Manuel Hidalgo. (2011) MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts. Clinical Cancer Research 17:9, pages 2799-2806.
Crossref
Crossref
Bastiaan Evers, Thomas Helleday & Jos Jonkers. (2010) Targeting homologous recombination repair defects in cancer. Trends in Pharmacological Sciences 31:8, pages 372-380.
Crossref
Crossref